The global Antimicrobial Susceptibility Testing (AST) market, valued at USD 3.42 billion in 2023, is projected to reach USD 5.35 billion by 2032, growing at a robust CAGR of 5.1% during the forecast period from 2025 to 2033. AST plays a pivotal role in combating antimicrobial resistance (AMR), a growing global health crisis caused by the overuse and misuse of antibiotics. This testing method enables healthcare providers to identify the most effective antimicrobial therapy, minimizing treatment failures and the spread of resistant pathogens.
The market's expansion is driven by the rising incidence of drug-resistant infections and an increasing focus on personalized medicine, where tailored treatments demand precise diagnostic solutions like AST. Government initiatives, such as the U.S. National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) and the Global Antibiotic Resistance and Usage Surveillance System (GLASS), are further bolstering the adoption of AST technologies. These efforts reflect the global commitment to reducing AMR through improved diagnostics and therapeutic strategies.
Technological advancements, particularly in automated AST systems, are reshaping the industry landscape. Automated systems offer higher accuracy, reduced errors, and faster turnaround times compared to manual methods. Recent innovations, such as rapid AST solutions capable of delivering results within hours, are accelerating their adoption in clinical and research settings. Companies like NanoSynex Ltd. and COPAN Diagnostics are at the forefront, introducing next-generation AST tools to the market.
Regional dynamics reveal North America as the dominant market, supported by advanced healthcare infrastructure, a high prevalence of multidrug-resistant infections, and substantial investments in R&D. Meanwhile, the Asia-Pacific region is expected to exhibit the fastest growth, driven by increasing healthcare expenditures, growing awareness of AMR, and initiatives to modernize healthcare systems. Europe also plays a significant role, benefiting from supportive policies and a focus on technological innovation.
Major market players included in this report are:
Thermo Fisher Scientific Inc.
BD (Becton, Dickinson, and Company)
bioMerieux SA
Danaher Corporation
Bio-Rad Laboratories Inc.
Merck & Co., Inc.
Siemens Healthineers
Creative Diagnostics
F. Hoffmann-La Roche Ltd
Hi-Media Laboratories Pvt. Ltd.
ELITechGroup
COPAN Diagnostics Inc.
Agilent Technologies Inc.
Beckman Coulter Inc.
NanoSynex Ltd.
The detailed segments and sub-segments of the market are explained below:
By Product:
Manual Tests
MIC Strips
Susceptibility Testing Disks
Susceptibility Plates
Automated Instruments
Consumables & Media
By Technique:
Disk Diffusion
Automated AST
Etest Method
Dilution
Others
By Application:
Drug Development
Susceptibility Testing
Others
By End-Use:
Hospitals
Diagnostic Laboratories
Biotechnology & Pharmaceutical Companies
Others
By Region:
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Italy
Sweden
Norway
Denmark
Asia-Pacific
China
India
Japan
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
UAE
Kuwait
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2025 to 2033
Key Takeaways:
Market Estimates & Forecast for 10 years from 2023 to 2033.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approaches.
Analysis of the competitive structure of the market.
Demand-side and supply-side analysis of the market.
